MediciNova Inc

NASDAQ MNOV

Data sourced from

and

Download Data

MediciNova Inc Capital Expenditure To Sales 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 30, 2023: -99.99%

MediciNova Inc Capital Expenditure To Sales 1 year YoY Change (%) is -99.99% for the Trailing 12 Months (TTM) ending September 30, 2023. The capital expenditure ratio measures the proportion of a company's revenue allocated to capital expenditures. It is calculated by dividing capital expenditures by revenue. This ratio indicates the extent to which a company invests in long-term assets relative to its sales. A higher ratio suggests a higher level of investment in the expansion and improvement of the company's asset base. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

MediciNova Inc Capital Expenditure To Sales for the Trailing 12 Months (TTM) ending March 31, 2022 was 3.09%, a 379.80% change year over year.
MediciNova Inc Capital Expenditure To Sales for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.64%.

NASDAQ: MNOV

MediciNova Inc

CEO	Dr. Yuichi Iwaki M.D., Ph.D.
IPO Date	Feb. 8, 2005
Location	United States
Headquarters	4275 Executive Square, La Jolla, CA, United States, 92037
Employees	13
Sector	Healthcare
Industry	Biotechnology

Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Key trends